Patient stories are powerful and that’s exactly why pharma want to use them.

In this episode, Rina and Jean analyse three AstraZeneca videos that used patient testimony describing treatment as “the best”, and why that language ultimately led to PMCPA breaches.

A must-listen for anyone approving patient-facing or patient-led materials under the ABPI Code.

(Case/0360/11/24 & /0355/11/24 & /0377/11/24)

In this episode, Rina and Jean dissect the new PMCPA social media guidance and highlight three key changes that add clarity for pharma companies.

Essential listening for anyone signing off or posting pharma content online.

The PMCPA has published 14 page guidance on Package Deals. We cut through the fluff and tell you what you need to know & why reviewing existing arrangements now matters for compliance and transparency.

Can a venue name alone imply excess? Rina and Jean unpack a recent case (Case/0440/01/25) where a meeting held at a “beach hotel” was perceived as lavish. They discuss how optics, assumptions, and language can affect judgment, and why facts still matter most in compliance decisions.

As MLR queues grow, complexity increases & review pain/boredom set in...there's good news for everyone!

Rina & Jean are joined by Harry Bliss & Dan Bentley from Siguru to discuss how AI can help approval teams move from bottleneck to breakthrough, without compromising compliance.

To find out more about AI-enabled MLR support, visit www.siguru.ai

Rina and Jean look ahead to UK pharma compliance in 2026, including likely complaint hotspots, familiar risk areas and the big question of PMCPA modernisation.

Two recent PMCPA cases (0273 & 3882) highlight a surprisingly simple point: using images that don’t reflect real patients doesn’t automatically mean a breach. We unpack what the rulings tell us about context, accuracy and visual representation in pharma comms - and why it matters for your next campaign. Images can be seen here.

When is a medicine… not a medicine — at least according to the PMCPA? 🤔In this episode, we dig into a fascinating case (AUTH/3880/2/24) where the ruling found no promotion of a medicine on social media. What crossed the line, what didn’t and what does it mean for your next post?

Speakers confirmed, slides ready… but no one shows up. 😬What do you do when a pharma meeting has no audience? Cancel? Pay? Re-run? We chat through compliance, optics and common-sense calls in this scenario.

The PMCPA says (currently) most complaints still stem from social media - and they’re now hinting at a cease-and-desist approach. We unpack what that could mean for pharma whilst everyone is still guessing what “promotional” really means...